1American Cancer society (2016) Breast Cancer Facts and Figures 2015 - 2016.
2Andre F, Zielinski CC (2012) Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann. Oncol 23 : 46-51.
3Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. The lancet oncology 8: 235-244 .
4Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population‐based incidence rates of triple‐negative breast cancer among young African‐American women : Implications for breast cancer screening recommendations 117: 2747-2753.
5Dietze EC, Sistrunk C, Miranda-Carboni G, O'Regan R, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15 : 248-254.
6Chu QD, Henderson AE, Ampil F, Li BD (2012) Outcome for patients with triple-negative breast cancer is not dependent on race/ethnicity. Int J Breast Cancer 2012:764570.
7Lin NU, Vanderplas A, Hughes ME et al. (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network. Cancer 118: 5463-5472.
8Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX (2013) Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat 13: 281-289.
9Huang Y (2013) Expansion Research Capability to Study Comparative Effectiveness in Complex Patients.
10Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7: 4-13.
11Nishimura R, Arima N (2008) Is triple negative a prognostic factor in breast cancer? Breast Cancer. 15: 303-308 .
12Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype. Cancer. 109: 1721-1728.
13Schneider BP, Winer EP, Foulkes WD et al. (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14: 8010-8018.
14Narod SA, Dent RA, Foulkes WD (2015) CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015-Still in the Ballpark. Foulkes WD. Clin. Cancer Res. 21: 3813-3814.
15Zhang L, Fang C, Xu X, Li A, Cai Q, et al.(2015) Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. BioMed research international 2015: 357485.
16Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. The lancet oncology. 14: 933-942.
17Zumsteg ZS, Morrow M, Arnold B et al. (2013) Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Annals of surgical oncology 20: 3469-3476.
18Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. (2014) New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin. Cancer Res 20: 782-790.
19Lund MJ, Trivers KF, Porter PL et al. (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res. Treat. 113(2), 357-370 .
20Sprague BL, Trentham‐Dietz A, Gangnon RE et al. Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer 117 : 1542-1551.
21Bustami RT, Shulkin DB, O'Donnell N, Whitman ED (2014) Variations in time to receiving first surgical treatment for breast cancer as a function of racial/ethnic background: a cohort study. JRSM Open. 5: 2042533313515863.
22 Gagliato Dde M, Gonzalez-Angulo AM, Lei X et al. (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J. Clin. Oncol 32: 735-744.
23Smith EC, Ziogas A, Anton-Culver H (2013) Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity. JAMA surgery 148: 516-523.
24 Zhu W, Perez EA, Hong R, Li Q, Xu B(2015) Age-related disparity in immediate prognosis of patients with triple-negative breast cancer: a population-based study from SEER cancer registries. PloS one 10: e0128345 .
25Lee E, McKean-Cowdin R, Ma H et al. (2011) Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J. Clin. Oncol. 29: 4373-4380.
26Keenan T, Moy B, Mroz EA, Ross K, Niemierko A et al. ( 2015) Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J. Clin. Oncol. 33: 3621-3627 .
27Sullivan HC, Oprea-Ilies G, Adams AL et al. (2014) Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. Appl. Immunohistochem. Mol. Morphol. 22: 17-23.
28 Sturtz LA, Melley J, Mamula K, Shriver CD, Ellsworth RE (2014) Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. BMC Cancer. 14-62.
29Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D (2011) The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J. Natl. Cancer Inst. 103: 1101-1111.
30Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP (2010) Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J. Clin Oncol 28: 2038-2045.
31Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, et al. (2012) Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res. Treat. 135: 281-289.
32Griffiths RI, Gleeson ML, Valderas JM, Danese MD. (2014) Impact of undetected comorbidity on treatment and outcomes of breast cancer. Int. J. Breast Cancer 2014: 970780.
33Sogaard M, Thomsen RW, Bossen KS, Sorensen H, Norgaard M (2013) The impact of comorbidity on cancer survival: a review. Clin Epidemiol 5:3-29.
34Allemani C, Storm H, Voogd AC, Holli K, Izarzugaza I, et al. (2010) Variation in ‘standard care’for breast cancer across Europe: a EUROCARE-3 high resolution study. Eur. J. Cancer 46: 1528-1536.
35Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML (2005) Breast cancer treatment guidelines in older women. J Clin Oncol 23: 783-791.
36Eisinger F, Ronda I, Puig B, Camerlo J, Giovannini M, et al. (2007) Breast cancer guidelines—Physicians' intentions and behaviors. Int J Cancer 120: 1136-1140.
37Owusu C, Buist DS, Field TS, Lash TL, Thwin SS et al. (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26: 549-555.
38Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R et al. (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21: 1383-1389.
39Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, et al. (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21: 2268-2275.
40Boyd CM, Vollenweider D, Puhan MA (2012) Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. PloS one. 7: e41601.
41Lind KD (2011) Excluding older, sicker patients from clinical trials: issues, concerns, and solutions. AARP Public Policy Institute.
42Abdollah F, Sun M, Thuret R, Abdo A, Morgan M, et al. (2011) The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study. Cancer Causes & Control 22: 1085-1095.
43Kravdal H, Syse A (2011) Changes over time in the effect of marital status on cancer survival. BMC Public Health 11: 804.
44Goffredo P, Sosa JA, Roman SA (2013) Differentiated thyroid cancer presenting with distant metastases: a population analysis over two decades. World J. Surg. 37: 1599-1605.
45Celaya MO, Berke EM, Onega TL, Gui J, Riddle BL, et al. (2010) Breast cancer stage at diagnosis and geographic access to mammography screening (New Hampshire, 1998–2004). Rural Remote Health 10: 1361.
46Osborne C, Ostir GV, Du X, Peek MK, Goodwin JS (2005) The influence of marital status on the stage at diagnosis, treatment, and survival of older women with breast cancer. Breast Cancer Res. Treat. 93: 41-47.
47Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I (2006) Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol 24: 1105-1111.
48Madadi M, Zhang S, Yeary KHK, Henderson LM (2014) Analyzing factors associated with women’s attitudes and behaviors toward screening mammography using design-based logistic regression. Breast Cancer Res. Treat. 144: 193-204
49Alford SH, Leadbetter S, Rodriguez JL, Hawkins NA, Scholl LE, et al.(2015) Cancer screening among a population-based sample of insured women. Preventive medicine reports. 2:15-20.
50Patel K, Kanu M, Liu J, Bond B, Brown E, et al. (2014) Factors influencing breast cancer screening in low-income African Americans in Tennessee. J Community Health 39: 943-950.
51Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, et al. (2013) Marital status and survival in patients with cancer. J Clin Oncol 31: 3869-3876.
52DiMatteo MR (2004) Social support and patient adherence to medical treatment: a meta-analysis. Health psychology. 23: 207-218.